| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_629f55715803854f5ac828876b6e3e20 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6848
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0676
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4702
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6839
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6851 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N27-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
2021-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c202b77630369c570a3ca59475cfe85b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75b92dc5512f83b419ec869799027d90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_233deaf46f69839cee9cebe8bbe1eb22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0dbecf1849c3f9429d24f505d34ac0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a21f4e2719aaf85597926e209717b9b6 |
| publicationDate |
2021-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113663054-A |
| titleOfInvention |
Use and cells of ISL1 in the preparation of drugs for inhibiting early ferroptosis of transplanted islets |
| abstract |
The invention relates to the field of pancreatic islet transplantation, in particular to the use and cells of ISL1 in the preparation of a drug for inhibiting early ferroptosis of transplanted pancreatic islets. Islet cells overexpressing ISL1 were constructed by adenovirus to obtain islet cells overexpressing ISL1. Overexpression of lentivirus in rat β-cell INS-1 and knockdown of ISL1 were used to detect the expression changes of ferroptosis-related proteins (GPX4 and ACSL3) and apoptosis-related proteins. Protective effect: Using the adenovirus of EcoRI MCS‑ISL1 to construct rat and human islet cells overexpressing ISL1, it was confirmed that ISL1 inhibits ferroptosis of transplanted islets by promoting the expression of ACSL3 in the islet cells. It lays a solid foundation for genetically modifying human islet cells to improve the survival of transplanted islets and for islet transplantation to be widely used in clinical practice. The constructed cells can be used for experiments and the possibility of islet transplantation. |
| priorityDate |
2021-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |